

[362] NOVELLUSDx - SOLVING THE MISSING PIECE OF CANCER DX

Haim Gil-Ad¹, ¹ Novellusdx Ltd.

ABSTRACT TEMPLATE for Company Presentations

The maximum number of words for this abstract is 300 words.

You may delete the section instructions, leaving only the bolded bullet title.

Questions for Biotech/Pharma; Medical Devices and Health IT/Digital Health categories are:

- **Investment Rational**
Briefly describe the company's technology or therapeutic focus. The market opportunity, progress made to date key partnerships or joint ventures. Management strengths
- **Business Strategy**
NovellusDx is an early commercial phase, Jerusalem-based company dedicated to delivering the actionable intelligence that oncologists require to choose the right therapy for each patient. NovellusDx provides comprehensive oncogenic activity profiling of individual patient tumors including charting the full landscape of known and unknown mutations that drive cancer's progression, as well as the hierarchy of driver mutations and mutation Cross-Talk. By measuring the activity of signaling pathways, NovellusDx solution can assess the oncogenic activity of mutations and their response to targeted drugs for every patient individually, without any prior knowledge of the mutations. Also, NovellusDx solution helps biopharma companies identify expanded subgroups of cancer patients who are likely to respond to existing therapies, stratify patients to enable more focused and efficient trials and isolate new mutations to target.
- **Core Technology**
See above
- **Product Profile/Pipeline**
Early commercial phase, dozens of partnerships
- **What's Next?**
Increase capacity

Question for Service provider category are:

- **Main Service:**
See above
- **Key Strengths:**
See above
- **Experience with Israeli Companies:**
Please provide examples if relevant
- **Key Markets:**
Mainly US